Idorsia Ltd is a Swiss biopharmaceutical company headquartered in Allschwil near Basel, specializing in the discovery, development, and commercialization of innovative small-molecule medicines for unmet medical needs. Its purpose is to transform therapeutic options in areas such as central nervous system disorders, cardiovascular conditions, immunology, and rare diseases like Fabry disease. Notable products include QUVIVIQ (daridorexant), a dual orexin receptor antagonist commercially available in the US, Europe, and other regions for treating insomnia by addressing both nighttime and daytime symptoms. JERAYGO (aprocitentan), a dual endothelin receptor antagonist for resistant hypertension, has received approvals in the EU, UK, Switzerland, and Canada. The pipeline features advanced assets like lucerastat for Fabry disease, advancing toward potential registration by 2029, and Phase 3 programs including selatogrel for acute myocardial infarction outlicensed to Viatris. Idorsia operates as a biotech hub in Europe with approximately 938 employees, focusing on high-impact therapies through strategic partnerships and a robust drug discovery engine. In the financial markets, it represents a small-growth player in the biotechnology sector, emphasizing innovation amid evolving clinical milestones.